TNMG Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.14
- P/S (TTM)
- 0.02
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -164.6%
- Operating margin
- -25.9%
- Revenue growth YoY
- 5.7%
- Dividend yield
- —
- Beta
- 0.76
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About TNL Mediagene Ordinary Shares
Company profileTNL Mediagene Ordinary Shares is an innovative biopharmaceutical firm focused on developing and commercializing cutting-edge therapies for oncology and autoimmune disorders. The company boasts a strong pipeline driven by advanced technologies and strategic collaborations, positioning it for significant growth in the evolving healthcare market. TNL Mediagene's commitment to scientific excellence and patient-centered solutions reinforces its aim to enhance patient outcomes while addressing critical health challenges, thereby establishing itself as a notable entity within the biopharmaceutical…
Classification
- Sector
- Communication Services
- Industry
- Publishing
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 23-2 MARUYAMACHO, TOKYO, JAPAN
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
